The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with ...

Guillain-Barré Syndrome (GBS) is a rare neuromuscular ... One-quarter will require mechanical ventilation. Close to one-fifth can't walk within one year of treatment, and about half experience ...

Guillain–Barré syndrome (GBS) is an autoimmune acute ... Mental disturbances were associated with more severe disease, assisted ventilation, higher levels of protein and lower levels of ...

This announcement was made alongside the reveal of positive Phase 3 results for Tanruprubart, a monoclonal antibody that can block C1q and can potentially halt neuroinflammation and nerve damage in ...

Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that ...

Annexon, Inc. (NASDAQ:ANNX) on Tuesday presented data for its late-stage targeted therapy, tanruprubart (formerly ANX005), ...

To beef up its case for tanruprubart, Annexon also announced on Wednesday that a real-world study of the drug likewise showed a “rapid increase in muscle strength” versus current standards of care in ...

Peruvian authorities Saturday declared a 90-day nationwide sanitary emergency due to the “unusual increase” in cases of Guillain-Barré Syndrome, it was reported in Lima. As per President Dina ...

Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder where the immune system attacks peripheral nerves, causing weakness, tingling, and sometimes paralysis. It often follows infections ...

Five-year-olds can be goofy. That was my first thought several years ago when my son stumbled and fell to the ground.